Physician profile
Ernesto Gerardo
NPI 1871673038
$897.90
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $393 · 2020: $160 · 2021: $238 · 2022: $107.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $153.48 | 2019-2021 | |
| Ironshore Pharmaceuticals INC. | $145.15 | 2019-2020 | |
| Neos Therapeutics, LP | $114.31 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $102.12 | 2020-2022 | |
| Tris Pharma INC | $60.47 | 2020-2021 | |
| Shire North American Group INC | $57.51 | 2019 | |
| Cranial Technologies, INC | $52.32 | 2019-2020 | |
| Sobi, INC | $35.97 | 2019 | |
| Supernus Pharmaceuticals, INC. | $34.56 | 2021-2022 | |
| Glaxosmithkline, LLC. | $32.70 | 2022 | |
| Genentech USA, INC. | $28.69 | 2019-2020 | |
| Corium, LLC | $20.70 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $18.35 | 2021 | |
| Phadia US INC. | $15.20 | 2021 | |
| Dermira, INC. | $14.88 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adlon Therapeutics L.P. | $11.49 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ernesto Gerardo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.